Advanced cutaneous T-cell lymphoma on or following two systemic therapies

Female participants must have a negative serum pregnancy test within 3 days of the first dose of vorinostat

Female participants must have finished menopause, or are surgically sterilized, or agree to use 2 adequate barrier methods of contraception

Male participants must agree to use 2 adequate barrier methods of contraception

To be treated on extension phase of study participant must have been treated on the base study for Protocol 042

Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)